Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974037 | 0.90 | KCNH2 (0.43) | KCNH2PDE10ANOS2 | |
| SCHEMBL6501711 | 0.85 | KCNH2 (0.40) | KCNH2PDE10ANOS2TLR8TGFBR1 | |
| SCHEMBL2015923 | 0.82 | PDE10A (0.36) | KCNH2PDE10A | |
| SCHEMBL7202960 | 0.81 | IRAK4 (0.41) | KCNH2PDE10ANOS2 | |
| SCHEMBL25379810 | 0.78 | LIPG (0.40) | — | |
| SCHEMBL1404092 | 0.78 | KCNH2 (0.83) | KCNH2NOS2TLR7TLR8 | |
| SCHEMBL7798225 | 0.78 | PDE10A (0.37) | KCNH2PDE10ANOS2 | |
| SCHEMBL25378990 | 0.77 | HTR1A (0.40) | KCNH2 | |
| SCHEMBL6500417 | 0.76 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL18586993 | 0.75 | MAPT (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KCNH2 4591/4885PDE10A 4218/4885NOS2 1264/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | KCNH2 4591/4885PDE10A 4218/4885NOS2 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.